Press releaseGlobe Newswire
Pyxis Oncology
PYXS · NASDAQ
$1.84+$0.08 (+4.55%)TodayMarket closed ·
Prev close $1.76
Latest news
- Press releaseGlobe Newswire
Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering
- Press releaseGlobe Newswire
Pyxis Oncology Announces Proposed Public Offering
- NewsVandana Singh
Pyxis Oncology Analyst Flags Key Safety Liabilities from Cancer Drug
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releaseGlobe Newswire
Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
- NewsMohd Haider
Pyxis Oncology Stock Soars Over 5% Overnight: Here's What You Need to Know
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- Press releaseGlobe Newswire
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- Press releaseGlobe Newswire
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releaseGlobe Newswire
Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026
- Press releaseGlobe Newswire
Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
- Press releaseGlobe Newswire
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
- NewsVandana Singh
Analysts Sound Alarm On Pyxis Oncology's Tiny Trial
- NewsAvi Kapoor
Tesla To $444? Here Are 10 Top Analyst Forecasts For Friday
- NewsAvi Kapoor
Nasdaq Gains Over 200 Points; US Inflation Slows To 2.7%
- NewsAvi Kapoor
Dow Surges 400 Points; Accenture Earnings Top Views
- Press releaseGlobe Newswire
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Press releaseGlobe Newswire
Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results
- Press releaseGlobe Newswire
Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
- NewsAvi Kapoor
Nasdaq Edges Higher; Baidu Shares Fall After Q3 Results
- NewsAvi Kapoor
Crude Oil Gains 1%; Deere Posts Better-Than-Expected Earnings
- NewsAvi Kapoor
Dow Jumps Over 100 Points; Nvidia Posts Upbeat Earnings
- News
Market-Moving News for November 21st
- Press releaseGlobe Newswire
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024
- Press releasePRNewswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS)
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.